Literature DB >> 30336071

FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation.

Shaoqiang Cheng1, Yuanxi Huang1, Chun Lou1, Yanxia He2, Yue Zhang2, Qingyuan Zhang2.   

Abstract

FSTL1 is a protein coding gene associated with cell signaling pathway regulation and the progression of a variety of disorders. In this study, we hypothesized that FSTL1 increases oncogenesis in breast cancer by enhancing stemness and chemoresistance. RT-PCR and IHC revealed significantly higher FSTL1 mRNA and protein levels in TNBC than in non-TNBC specimens and in breast cancer cell lines. We then found that FSTL1 levels were significantly increased in chemoresistant cells. LIVE/DEAD, MTT cell viability and colony formation assays did in fact demonstrate that FSTL1 is required for CDDP and DOX chemoresistance in breast cancer cell lines. FSTL1 overexpression caused significant elevation of stem cell biomarkers, as well as breast cancer cell proliferation. To determine whether the Wnt/β-catenin signaling pathway is involved in the observed effects of FSTL1, we assessed levels of pathway target. TOP/FOP flash, colony formation, and tumor sphere formation assays indicated that FSTL1 activates Wnt/β-catenin signaling through integrin β3. We then sought to identify a microRNA (miRNA) that regulates FSTL1 activity. Luciferase assays demonstrated that miR-137 reduces FSTL1 mRNA and protein levels. Ultimately, our findings indicate that there is an miR-137/FSTL1/integrin β3/Wnt/β-catenin signaling axis in breast cancer cells that regulates stemness and chemoresistance.

Entities:  

Keywords:  FSTL1; Wnt signaling; breast cancer; chemoresistance; integrin β3; miR-137; stemness

Mesh:

Substances:

Year:  2018        PMID: 30336071      PMCID: PMC6370380          DOI: 10.1080/15384047.2018.1529101

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  47 in total

Review 1.  New insights into the mechanism of Wnt signaling pathway activation.

Authors:  Akira Kikuchi; Hideki Yamamoto; Akira Sato; Shinji Matsumoto
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

2.  miR-137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells.

Authors:  Ming Liu; Nan Lang; Meng Qiu; Feng Xu; Qiu Li; Qiulin Tang; Ji Chen; Xi Chen; Siyuan Zhang; Zhen Liu; Jitao Zhou; Yajie Zhu; Yu Deng; Yi Zheng; Feng Bi
Journal:  Int J Cancer       Date:  2011-03-15       Impact factor: 7.396

3.  DIP2A functions as a FSTL1 receptor.

Authors:  Noriyuki Ouchi; Yasuhide Asaumi; Koji Ohashi; Akiko Higuchi; Saki Sono-Romanelli; Yuichi Oshima; Kenneth Walsh
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

Review 4.  Recent trends in breast cancer incidence and mortality.

Authors:  James V Lacey; Susan S Devesa; Louise A Brinton
Journal:  Environ Mol Mutagen       Date:  2002       Impact factor: 3.216

5.  Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.

Authors:  Adel Tabchy; Vicente Valero; Tatiana Vidaurre; Ana Lluch; Henry Gomez; Miguel Martin; Yuan Qi; Luis Javier Barajas-Figueroa; Eduardo Souchon; Charles Coutant; Franco D Doimi; Nuhad K Ibrahim; Yun Gong; Gabriel N Hortobagyi; Kenneth R Hess; W Fraser Symmans; Lajos Pusztai
Journal:  Clin Cancer Res       Date:  2010-09-09       Impact factor: 12.531

6.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Authors:  W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544

7.  'See-saw' expression of microRNA-198 and FSTL1 from a single transcript in wound healing.

Authors:  Gopinath M Sundaram; John E A Common; Felicia E Gopal; Satyanarayana Srikanta; Krishnaswamy Lakshman; Declan P Lunny; Thiam C Lim; Vivek Tanavde; E Birgitte Lane; Prabha Sampath
Journal:  Nature       Date:  2013-02-10       Impact factor: 49.962

Review 8.  Standard of care and promising new agents for triple negative metastatic breast cancer.

Authors:  Patrizia Mancini; Antonio Angeloni; Emanuela Risi; Errico Orsi; Silvia Mezi
Journal:  Cancers (Basel)       Date:  2014-10-24       Impact factor: 6.639

9.  Effects of FSTL1 on cell proliferation in breast cancer cell line MDA‑MB‑231 and its brain metastatic variant MDA‑MB‑231‑BR.

Authors:  Jiaqiang An; Lulu Wang; Yuanli Zhao; Qiang Hao; Ying Zhang; Jingyi Zhang; Chun Yang; Li Liu; Wenjuan Wang; Dongliang Fang; Tao Lu; Yan Gao
Journal:  Oncol Rep       Date:  2017-09-26       Impact factor: 3.906

10.  Follistatin like-1 (Fstl1) is required for the normal formation of lung airway and vascular smooth muscle at birth.

Authors:  Xue Liu; Yingying Liu; Xiaohe Li; Jing Zhao; Yan Geng; Wen Ning
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

View more
  28 in total

1.  FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway.

Authors:  Ya-Kun Liu; Ya-Jing Jia; Shi-Hao Liu; Jing Ma
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-03       Impact factor: 3.333

2.  FSTL1 promotes growth and metastasis in gastric cancer by activating AKT related pathway and predicts poor survival.

Authors:  Mengjie Wu; Yongfeng Ding; Nan Wu; Junjie Jiang; Yingying Huang; Fanyu Zhang; Haiyong Wang; Quan Zhou; Yan Yang; Wei Zhuo; Lisong Teng
Journal:  Am J Cancer Res       Date:  2021-03-01       Impact factor: 6.166

Review 3.  Role of microRNA/lncRNA Intertwined With the Wnt/β-Catenin Axis in Regulating the Pathogenesis of Triple-Negative Breast Cancer.

Authors:  Xue Hu; Qiang Zhang; Wanying Xing; Wan Wang
Journal:  Front Pharmacol       Date:  2022-06-24       Impact factor: 5.988

Review 4.  MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells.

Authors:  Amir Sadra Zangouei; Maliheh Alimardani; Meysam Moghbeli
Journal:  Cancer Cell Int       Date:  2021-04-15       Impact factor: 5.722

Review 5.  The role of polyphenols in overcoming cancer drug resistance: a comprehensive review.

Authors:  Parisa Maleki Dana; Fatemeh Sadoughi; Zatollah Asemi; Bahman Yousefi
Journal:  Cell Mol Biol Lett       Date:  2022-01-03       Impact factor: 5.787

6.  MicroRNA‑137 exerts protective effects on hypoxia‑induced cell injury by inhibiting autophagy/mitophagy and maintaining mitochondrial function in breast cancer stem‑like cells.

Authors:  Qiongying Hu; Yun Yuan; Yeke Wu; Yongliang Huang; Ziyi Zhao; Chong Xiao
Journal:  Oncol Rep       Date:  2020-08-03       Impact factor: 3.906

Review 7.  Emerging Roles of Matricellular Proteins in Systemic Sclerosis.

Authors:  Daniel Feng; Casimiro Gerarduzzi
Journal:  Int J Mol Sci       Date:  2020-07-06       Impact factor: 5.923

8.  miR-200c-3p Regulates Epitelial-to-Mesenchymal Transition in Epicardial Mesothelial Cells by Targeting Epicardial Follistatin-Related Protein 1.

Authors:  Elena Pontemezzo; Eleonora Foglio; Enza Vernucci; Alessandra Magenta; Marco D'Agostino; Sara Sileno; Elena Astanina; Federico Bussolino; Laura Pellegrini; Antonia Germani; Matteo Antonio Russo; Federica Limana
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

9.  miR-137/ERRα axis mediates chemoresistance of nasopharyngeal carcinoma cells.

Authors:  Fei Liu; Chunsheng Gao; Wenjuan Wang; Jing Hu; Zuofeng Huang; Meng Liang; Shuo Li
Journal:  J Cell Commun Signal       Date:  2021-07-01       Impact factor: 5.782

10.  Long noncoding RNA HULC contributes to paclitaxel resistance in ovarian cancer via miR-137/ITGB8 axis.

Authors:  Bo Huang; Min Wei; Li Hong
Journal:  Open Life Sci       Date:  2021-07-01       Impact factor: 0.938

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.